|
| |
| | Deferoxamine Antidote: 2004 |
 | | Deferoxamine seemed to have no influence on the incidence of bacteraemia in the 39 study patients compared to a control group of 193 patients on haemodialysis, but not receiving deferoxamine. | | | Chemical modification of deferoxamine, by conjugating the drug to polysaccharides such as dextran and hydroxylethyl starch, has been investigated as a means of improving its efficacy. | | | Ferrioxamine in bile is most likely derived from the deferoxamine chelation of iron in the hepatocyte, except in the case of nephrectomised dogs (and humans). |
|
http://www.inchem.org/documents/antidote/antidote/deferoxamine.htm
|
|
| |
| | Iron-Chelating Therapy and the Treatment of Thalassemia -- Olivieri and Brittenham 89 (3): 739 -- Blood |
| | The most common difficulty associated with long-term therapy with subcutaneous deferoxamine is erratic compliance with therapy, which may decline as supervision of this regimen becomes increasingly the responsibility of the patient; objectively monitored compliance with deferoxamine is less than 70% in many older patients. | | | Deferoxamine mesylate, first introduced in short-term studies in iron-loaded patients in the early 1960s, gained acceptance as standard therapy over a decade later in countries able to support the high costs of this therapy. | | | Radiographs of the femoral and tibial metaphyses of a child treated with deferoxamine therapy. |
|
http://www.bloodjournal.org/cgi/content/full/89/3/739
|
|
| |
| | DEFEROXAMINE (Systemic) |
| | Deferoxamine may cause some people, especially younger patients, to have hearing and vision problems within a few weeks after they start taking it. | | | Deferoxamine is to be administered only by or under the immediate supervision of your doctor. | | | This medicine may be used for other conditions as determined by your doctor. |
|
http://www.medformation.com/ac/mm_usp.nsf/usp/203185b.htm
|
|
| |
| | Cancer Control Journal:Infections in Oncology |
| | Although prophylactic antifungal therapy is not warranted for all patients receiving deferoxamine, early recognition of mucormycosis in high-risk patients receiving deferoxamine may improve outcomes. | | | compared 26 patients who developed mucormycosis associated with deferoxamine therapy with 20 patients who received deferoxamine following dialysis. | | | An association between deferoxamine therapy and mucormycosis is evident even in settings without hemodialysis, |
|
http://www.moffitt.usf.edu/pubs/ccj/v4n2/department5.html
|
|
| |
| | Nancy F Olivieri , BSc, MD, FRCPC |
| | Recognizing the primary obstacle to survival in these patients as poor compliance with subcutaneous deferoxamine, we designed a novel delivery system of continuous ambulatory intravenous deferoxamine. | | | The second focus, arising out of the first, have focused on the development of new chelating agents as the use of deferoxamine, while lifesaving, is associated with erratic compliance and great expense. | | | The first research thrust has focused on the in vivo efficacy and toxicity of deferoxamine, the only available treatment for iron overload. |
|
http://www.uhnres.utoronto.ca/researchers/profile.php?lookup=4539
|
|
| |
| | The Cardiac Society of Australia and New Zealand - 48th ASM Abstracts |
| | Deferoxamine improved the blood flow response to methacholine (p<0.02 by two-way repeated measures ANOVA). | | | In an additional 5 normal subjects, deferoxamine had no effect on the blood flow response to methacholine. | | | However, deferoxamine had no effect on the response to sodium nitroprusside. |
|
http://www.csanz.edu.au/abstracts/48abstracts/325.htm
|
|
| |
| | Deferoxamine |
| | All people treated with deferoxamine should consult their prescribing doctor before using any iron-containing products. | | | Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. | | | Deferoxamine is a drug that binds to some metals and carries them out of the body. |
|
http://www.gianteagle.com/healthnotes/Drug/Deferoxamine.htm
|
|
| |
| | News - Long-Term Deferiprone May Protect Heart Against Toxic Iron Overload In Patients With Thalassaemia Major |
| | In the first retrospective analysis of the comparative effects of deferiprone and deferoxamine on mortality and cardiac morbidity in patients with thalassaemia major, long-term therapy with deferiprone was associated with a significant reduction in cardiac dysfunction over time and improved survival compare to deferoxamine. | | | Most patients with thalassaemia major die from iron-induced cardiac disease, despite chelation therapy with deferoxamine, and to date, no study has compared the frequency of cardiac complications and survival between deferiprone and deferoxamine in these patients. | | | On an average of 6 years follow-up, patients treated with deferiprone had significantly fewer cases of cardiac dysfunction (defined as worsening of pre-existing cardiac abnormalities or development of new cardiac disease) than patients treated with deferoxamine: 4% (2 of 54) vs. 20% (15 of 75), respectively (p=0.007). |
|
http://docguide.com/news/content.nsf/news/8525697700573E1885256D2100566B73
|
|
| |
| | Inhibitory effects of deferoxamine on UVB-induced AP-1 transactivation -- Kramer-Stickland et al. 20 (11): 2137 -- ... |
| | Rao,M.S. and Subbarao,V. (1997) The effect of deferoxamine on ciprofibrate-induced hepatocarcinogenesis in the rat. | | | Morris,S.F., Pang,C.Y., Lofchy,N.M., Davidson,G., Lindsay,W.K., Zuker,R.M. and Boyd,B. (1993) Deferoxamine attenuates ischemia-induced reperfusion injury in the skin and muscle of myocutaneous flaps in the pig. | | | Department of Radiation Oncology, The University of Arizona Health Sciences Center, Tucson, AZ 85724, USA |
|
http://carcin.oupjournals.org/cgi/content/full/20/11/2137
|
|
| |
| | Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane -- Elihu et ... |
| | This review was conducted to assess whether there is sufficient evidence for the clinical use of chelation therapy in cardiovascular disease based on original articles and abstracts published in the last 30 years, with emphasis placed on the most recent placebo-controlled studies. | | | Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane | | | Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane -- Elihu et al. |
|
http://www.jclinpharm.org/cgi/content/abstract/38/2/101
|
|
| |
| | ASH ONLINE |
| | Their results suggest that ICL670 is well tolerated and at least as effective as deferoxamine in promoting a negative iron balance in patients with iron overload. | | | Piga and colleagues treated 71 patients with thalassemia and transfusional iron overload with either ICL670 at 10 mg/kg/day, ICL670 at 20 mg/kg/day, or deferoxamine 40 mg/kg/day, subcutaneously 5 days/week. | | | Deferiprone (L1) has been the most extensively studied, but produces a negative iron balance in only 52% of patients, is less effective than parenteral deferoxamine, and has significant side effects. |
|
http://www.hematology.org/meeting/2002/newsdaily/Thalassemia.cfm
|
|
| |
| | DEFEROXAMINE (Injection) (Injectable) Prescription Drug Information, Cost, Price, Side Effects, and More. |
| | Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products. | | | DEFEROXAMINE (Injection) (Injectable) is used for the Treatment | | | DEFEROXAMINE (Injection) (Injectable) Drug and Prescription Information, Side Effects, Use, and Dosage |
|
http://healthdigest.org/DEFEROXAMINE-(Injection)-(Injectable)_2868_PRO.php
|
|
| |
| | Care Coordination for Patients with Sickle Cell Disease |
| | MLPs should educate children and their families about the serious complications of iron overload, and carefully monitor compliance with chelation therapy. | | | When iron overload is documented, patients should be started on iron chelation therapy. | | | Parenteral deferoxamine mesylate (Desferal) is the only iron chelator available at this time and is used primarily as a subcutaneous daily infusion. |
|
http://sickle.bwh.harvard.edu/coordination.html
|
|
| |
| | Coronary vascular injury following transient coronary artery occlusion: prevention by pretreatment with deferoxamine, ... |
| | Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model | | | Coronary vascular injury following transient coronary artery occlusion: prevention by pretreatment with deferoxamine, dimethylthiourea and N-2- mercaptoproprionyl glycine -- Patterson 266 (3): 1528 -- Journal of Pharmacology And Experimental Therapeutics | | | 30-min occlusion were reduced by acute deferoxamine and dimethylthiourea, |
|
http://jpet.aspetjournals.org/cgi/content/abstract/266/3/1528
|
|
| |
| | eMedicine - Toxicity, Iron : Article by Kathryn Clark, MD |
| | No clear end-point of therapy exists; however, indications for cessation include significant resolution of shock and acidosis. | | | Pulmonary toxicity (ie, acute respiratory distress syndrome [ARDS], tachypnea) and hypotension have been described, especially if patients are treated with deferoxamine for more than 24 hours. | | | Because these end-points are arbitrary, observe the patient for the recurrence of toxicity 2-3 hours after the deferoxamine has been stopped. |
|
http://www.emedicine.com/ped/topic2835.htm
|
|
| |
| | Deferoxamine |
| | Hypersensitivity to deferoxamine or any component of the formulation; patients with anuria, primary hemochromatosis | | | Use with caution in patients with severe renal disease, pyelonephritis; may increase susceptibility to Yersinia enterocolitica. | | | When severe symptoms are not present, the I.M. route may be preferred; however, the use of deferoxamine in situations where the serum iron concentration is <500 |
|
http://www.musc.edu/pharmacyservices/Drugs/D/Deferoxamine.htm
|
|
| |
| | U.S. Newswire : Releases : "Cardiac Deaths Among Thalassemia Patients in U.S. Preventable..." |
| | The study, presented by Dr. Caterina Borgna-Pignatti from Ferrara, Italy, involved more than 500 patients treated with deferiprone or deferoxamine during the past 9 years. | | | In this retrospective study, when the patients who used deferiprone were compared to those who used only deferoxamine, it was found that heart disease and death were significantly more frequent in those who had not received deferiprone. | | | Cardiac disease as a result of heart iron accumulation is the most prevalent cause of death among patients with thalassemia. |
|
http://releases.usnewswire.com/GetRelease.asp?id=44771
|
|
| |
| | WebMD Health - Patient Handout for Deferoxamine Mesylate Injection |
| | What should I know before taking this medicine? | | | WebMD Health - Patient Handout for Deferoxamine Mesylate Injection | | | A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment. |
|
http://my.webmd.com/drugs/drug-8766-Deferoxamine+Mesylate+Injection.aspx?...
|
|
| |
| | New drug gives good results in treating chronic iron overload, Novartis |
| | Non-inferiority was demonstrated, however, in those patients treated with ICL670 at 20 and 30 mg/kg/day. | | | In the Phase III trial, four patients (1.4%) in the deferoxamine group and eight patients (2.7%) in the ICL670 group had discontinued therapy due to any adverse events. | | | In a related, open-label Phase II trial presented at ASH, data from a study of 184 patients with myelodysplastic syndrome (MDS), other rare anemias, and patients with thalassemia unable to take deferoxamine therapy, also demonstrated maintenance or reduction of absolute LIC values in patients treated with ICL670 at doses of 20 and 30 mg/kg/day. |
|
http://www.medicalnewstoday.com/medicalnews.php?newsid=17442
|
|
| |
| | Environmental Health Perspectives 105, Supplement 5, September 1997: Article by Broaddus et al. |
| | -- Environ Health Perspect 105(Suppl 5):1147-1152 (1997) Key words : oxygen radicals, annexin V, flow cytometry, deferoxamine, internalization | | | Reactive oxygen species mediate toxicity from asbestos in many in vitro and in vivo models ( 12,16,40), although their role in injury to mesothelial cells is unclear ( 13-15). | | | Fibers and control particles that had been autoclaved and found to be free of endotoxin by Limulus assay (Whittaker Bioproducts, Walkersville, MD) were sonicated (60 W for 5 sec) (Branson 450 sonifier, Danbury, CT) in cell culture medium, then added to cells at the desired surface concentration. |
|
http://ehp.niehs.nih.gov/members/1997/Suppl-5/broaddus-full.html
|
|
| |
| | Local Libraries |
| | Rockville, MD : U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Services Research and Health Care Technology Assessment, [1987] | | | Hemoperfusion in conjunction with deferoxamine for the treatment of aluminum toxicity or iron overload in patients with end-stage renal disease | | | WorldCat is provided by OCLC Online Computer Library Center, Inc. on behalf of its member libraries. |
|
http://worldcatlibraries.org/wcpa/ow/7421e72c3f325695a19afeb4da09e526.html
|
|
| |
| | News - European Agency Extends Marketing Authorization of Ferriprox (Deferiprone), for Thalassemia Inadequately Treated ... |
| | The new indication is "Ferriprox is indicated for the treatment of iron overload in patients with thalassemia major when deferoxamine therapy is contraindicated or inadequate". | | | Prior to the approval of Ferriprox, an oral iron chelator, thalassemia patients had only one treatment option - daily infusions of deferoxamine, subcutaneously infused for up to twelve hours each night, resulting in local pain and compliance problems for some patients. | | | "The EC's decision is a major advance in treatment options for thalassemia patients who are inadequately responsive to deferoxamine. |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256E920066094A
|
|
| |
| | [No title] |
| | We therefore concluded that deferoxamine mesylate may be a useful chemotherapeutic agent in the treatment of breast cancer, when used in combination with standard chemotherapeutic regiments or with other agents that interfere with iron metabolism, and further that the restricting of iron intake should be considered when planning chemotherapy for all cancer patients. | | | At the end of the experiments measurement of serum iron proved that these treatments caused iron deficiency, but there was no significant treatment related alteration in blood hematocrit. | | | Iron absorption is affected by the form in which iron is presented to the digestive tract, and inorganic iron ions change oxidation state during the absorption process. |
|
http://herbivore.7h.com/lowirondiet.html
|
|
| |
| | Metabolism and Pharmacokinetics of N ,N11-Diethylnorspermine in a Cebus apella Primate Model -- Bergeron et al. 60 ... |
| | The Development of Iron Chelators for Clinical Use, : 373-394, CRC Boca Raton 1994. | | | Brossat B., Straczek J., Belleville F., Nabet P., Metz R. Determination of free and total polyamines in human serum and urine by ion pairing high-performance liquid chromatography using a radial compression module. | | | Bergeron R. J., Streiff R. R., Wiegand J., Luchetta G., Creary E. A., Peter H. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. |
|
http://cancerres.aacrjournals.org/cgi/content/full/60/16/4433
|
|
| |
| | Tramadol, buy tramadol, Ultram, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, hair ... |
| | Deferoxamine, allopurinol or oxypurinol were used as test substances. | | | Deferoxamine, allopurinol and oxypurinol have previously been shown to be neuroprotective in vivo during or directly after hypoxia-ischemia. | | | Deferoxamine, allopurinol and oxypurinol are not neuroprotective after oxygen/glucose deprivation in an organotypic hippocampal model, lacking functional endothelial cells. |
|
http://darwinpharmacy.com/ref-allopurinol/allopurinol-research-abs3.495.html
|
|
|
